Compare WKHS & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WKHS | OSRH |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4M | 18.4M |
| IPO Year | 2008 | N/A |
| Metric | WKHS | OSRH |
|---|---|---|
| Price | $3.50 | $0.41 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $21.00 | N/A |
| AVG Volume (30 Days) | 69.6K | ★ 348.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $763,173.00 | N/A |
| Revenue This Year | $81.01 | N/A |
| Revenue Next Year | $34.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.19 | $0.38 |
| 52 Week High | $11.80 | $4.33 |
| Indicator | WKHS | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 36.86 | 35.85 |
| Support Level | $0.90 | $0.39 |
| Resistance Level | $6.00 | $0.47 |
| Average True Range (ATR) | 0.22 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 37.66 | 20.82 |
Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric delivery trucks and drone systems, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.